For additional safety information, please talk to your doctor and see the full Prescribing Information for EYLEA HD and EYLEA. Regeneron (NASDAQ: REGN) is a leading biotechnology company that ...
Hosted on MSN1mon
Regeneron projects EYLEA HD growth with new approvals and prefilled syringe launch in 2025CEO Leonard Schleifer highlighted 10% revenue growth in Q4 2024, attributed to strong performance from Dupixent, Libtayo, and EYLEA HD. He emphasized the acceleration in EYLEA HD uptake expected ...
Hosted on MSN2mon
Regeneron Culls Losses After High-Dose Eylea Sales DisappointDuring the December quarter, Regeneron Pharmaceuticals' Eylea HD generated $305 million in U.S. sales, missing forecasts for $411 million, according to FactSet. Offsetting that, standard Eylea ...
Sales of the EYLEA HD more than doubled to $305 million. The medication was approved for use in patients with certain eye conditions by the Food and Drug Administration in August 2023. For 2025 ...
LONDON, GREATER LONDON, UNITED KINGDOM, January 24, 2025 /EINPresswire / -- What's the Growth Trajectory of the Eylea HD Market in Recent and Upcoming Years? The eylea HD market has shown immense ...
today announced the first presentation of positive results from the Phase 3 QUASAR trial investigating EYLEA HD® (aflibercept) Injection 8 mg for the treatment of patients with macular edema ...
Sales of the EYLEA HD more than doubled to $305 million. The medication was approved for use in patients with certain eye conditions by the Food and Drug Administration in August 2023. For 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback